Article
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer.
ESMO open - 1 Jun 2023
Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D, Belli A, Izzo F, Avallone A, Selvaggi F, Menegon Tasselli F, Santaniello W, Franco R, Puig I, Ramirez L, Chicote I, Mancuso F, Caratu G, Serres X, Fasani R, Jimenez J, Ros J, Baraibar I, Mulet N, Della Corte C M, Troiani T, Vivancos A, Dienstmann R, Elez E, Palmer H G, Tabernero J, Martinelli E, Ciardiello F, Argilés G
Abstract excerpt
BACKGROUND: Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an unmatched model to elucidate tumor resistance to therapy, due to their high capacity to resemble tumor characteristics. MATERIALS AND METHODS: We used viable tumor tissue from two cohorts of patients with mCRC, naïve or refractory to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.